Aquestive Therapeutics Inc
Aquestive Therapeutics Inc (AQST) Covered Calls
Aquestive Therapeutics Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 75.00%, high versus the past year. AQST's highest covered call setup is the $7.00 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 89.19% out of the money with 183 days to expiration, a 100.00% return until expiration, and a 199.45% theoretical annualized return. Across the setups shown, annualized returns run from 43.79% to 199.45% at strikes between $4.00 and $7.00, with 29 to 428 days to expiration, as of Nov 19, 2026.
Read more
Running AQST covered calls helps you generate income from Aquestive Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AQST covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If AQST stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AQST covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AQST covered call is worth writing.
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
| 2027-05-21 | 183 | 7.00 | 89.19 | 0.40 | 0.85 | 370.00 | 100.00 | 199.45 | -10.81 | +0.41 | 566 | 0.45 |
| 2027-02-19 | 92 | 5.00 | 35.14 | 0.15 | 0.40 | 145.00 | 39.19 | 155.48 | -4.05 | +0.33 | 9,809 | 0.25 |
| 2026-12-18 | 29 | 4.00 | 8.11 | 0.15 | 0.25 | 45.00 | 12.16 | 153.08 | -4.05 | +0.40 | 155 | 0.10 |
| 2027-05-21 | 183 | 6.00 | 62.16 | 0.40 | 1.05 | 270.00 | 72.97 | 145.55 | -10.81 | +0.46 | 1,117 | 0.65 |
| 2027-03-19 | 120 | 5.00 | 35.14 | 0.40 | 1.20 | 170.00 | 45.95 | 139.75 | -10.81 | +0.51 | 353 | 0.80 |
| 2027-05-21 | 183 | 5.00 | 35.14 | 0.85 | 1.35 | 215.00 | 58.11 | 115.90 | -22.97 | +0.59 | 662 | 0.50 |
| 2027-02-19 | 92 | 4.00 | 8.11 | 0.35 | 1.10 | 65.00 | 17.57 | 69.70 | -9.46 | +0.56 | 704 | 0.75 |
| 2027-05-21 | 183 | 4.00 | 8.11 | 0.95 | 1.50 | 125.00 | 33.78 | 67.38 | -25.68 | +0.65 | 886 | 0.55 |
| 2027-03-19 | 120 | 4.00 | 8.11 | 0.30 | 1.45 | 60.00 | 16.22 | 49.32 | -8.11 | +0.59 | 42 | 1.15 |
| 2028-01-21 | 428 | 5.00 | 35.14 | 0.60 | 1.60 | 190.00 | 51.35 | 43.79 | -16.22 | +0.59 | 396 | 1.00 |
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - Specialty & Generic
- SectorHealthcare
- IV Rank75.00% High
- Market cap (M$)435
- 52 weeks high-48.66%
- 52 weeks low18.09%
- Analyst recommendationStrong Buy
1.00 - Target price$9.33
169.65% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-03
- P/E—
- Future P/E—
- EPS (ttm)-0.64
- EPS growth next 5 years22.72%
As of Nov 20, 2026